Search Results - "Wernli, M"

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants by Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J

“…Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day ( n =400) could be optimized by doubling the…”
Get full text

Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature by SCHWAPPACH, D.L.B., WERNLI, M.

“…SCHWAPPACH D.L.B. & WERNLI M. (2010) European Journal of Cancer Care19, 285–292
Medication errors in chemotherapy: incidence, types and involvement of patients…”
Get full text

Lactic acid fermentation of human urine to improve its fertilizing value and reduce odour emissions by Andreev, N., Ronteltap, M., Boincean, B., Wernli, M., Zubcov, E., Bagrin, N., Borodin, N., Lens, P.N.L.

“…During storage of urine, urea is biologically decomposed to ammonia, which can be lost through volatilization and in turn causes significant unpleasant smell…”
Get full text

The rotational excitation of HCN and HNC by He: new insights on the HCN/HNC abundance ratio in molecular clouds by Sarrasin, E., Abdallah, D. Ben, Wernli, M., Faure, A., Cernicharo, J., Lique, F.

“…Modelling of molecular emission from interstellar clouds requires the calculation of rates for excitation by collisions with the most abundant species. The…”
Get full text

Fast LiH Destruction in Reaction with H: Quantum Calculations and Astrophysical Consequences by Bovino, S, Wernli, M, Gianturco, F. A

Get full text

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study by BETTICHER, D. C, HSU SCHMITZ, S.-F, SPILIOPOULOS, A, STAHEL, R, WEDER, W, STUPP, R, EGLI, F, FURRER, M, HONEGGER, H, WERNLI, M, CERNY, T, RIS, H.-B, TÖTSCH, M, HANSEN, E, JOSS, C, VON BRIEL, C, SCHMID, R. A, PLESS, M, HABICHT, J, ROTH, A. D

“…The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by…”
Get full text

Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis by Kump, E, Ji, J, Wernli, M, Häusermann, P, Erb, P

“…Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC)…”
Get full text

Barriers and facilitators to chemotherapy patients’ engagement in medical error prevention by Schwappach, D.L.B., Wernli, M.

“…Medical errors are a serious threat to chemotherapy patients. Patients can make contributions to safety but little is known about the acceptability of…”
Get full text

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity by Borner, M. M., Bernhard, J., Dietrich, D., Popescu, R., Wernli, M., Saletti, P., Rauch, D., Herrmann, R., Koeberle, D., Honegger, H., Brauchli, P., Lanz, D., Roth, A. D.

“…Background: To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination…”
Get full text

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) by Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Léger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., Ketterer, N., Wernli, M., Cerny, T., Schmitz, S.-F. Hsu

“…Background: Predictive factors of rituximab efficacy and its effect on the immune system are still not defined. Patients and methods: Three hundred and six…”
Get full text

Computing a Three-Dimensional Electronic Energy Manifold for the LiH + H ⇌ Li + H2 Chemical Reaction by Wernli, M, Caruso, D, Bodo, E, Gianturco, F. A

“…We present a new three-dimensional potential energy surface (PES) for the electronic ground state of the LiH + H ⇌ Li + H2 reaction and further analyze…”
Get full text

Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL by Heizmann, M., Itin, P., Wernli, M., Borradori, L., Bargetzi, M.J.

“…Paraneoplastic pemphigus is a severe mucocutaneous disease associated in most cases with B‐cell lymphoproliferative disorders. Independent of the course of the…”
Get full text

The effect of Rituximab on patients with follicular and mantle-cell lymphoma by Ghielmini, M., Schmitz, S.-F. Hsu, Bürki, K., Pichert, G., Betticher, D. C., Stupp, R., Wernli, M., Lohri, A., Schmitter, D., Bertoni, F.

“…Background: Clinical activity of the anti CD-20 monoclonal antibody Rituximab has been reported in patients with follicular lymphoma (FL) and mantle-cell…”
Get full text

Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer by Tan, E.H., Szczesna, A., Krzakowski, M., Macha, H.N., Gatzemeier, U., Mattson, K., Wernli, M., Reiterer, P., Hui, R., Pawel, J. Von, Bertetto, O., Pouget, J.C., Burillon, J.P., Parlier, Y., Abratt, R.

“…The objective of this trial was to compare two vinorelbine-based doublets with carboplatin (CBDCA-VC) or with gemcitabine (VG) in patients with stage IIIB–IV…”
Get full text

Efficient mobilization of PBSC with vinorelbine G-CSF in patients with malignant lymphoma by Heizmann, M, O'Meara, A C, Moosmann, P R, Heijnen, I A F M, Zuberbühler, M, Fernandez, P, Burger, J, Huber, A, Wernli, M, Bargetzi, M J

“…High-dose chemotherapy (HDT) and hematopoietic SCT are effective in patients with relapsing or refractory malignant lymphoma. Collection of sufficient numbers…”
Get full text

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial by MORANT, R, BERNHARD, J, GSCHWEND, A, HANSELMANN, S, HERING, F, SCHMID, H-P, DIETRICH, D, GILLESSEN, S, BONOMO, M, BORNER, M, BAUER, J, CERNY, T, ROCHLITZ, C, WERNLI, M

“…The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of…”
Get full text

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study by von Rohr, A., Schmitz, S.-F. H., Tichelli, A., Hess, U., Piguet, D., Wernli, M., Frickhofen, N., Konwalinka, G., Zulian, G., Ghielmini, M., Rufener, B., Racine, C., Fey, M. F., Cerny, T., Betticher, D., Tobler, A.

“…Background: To assess the activity and toxicity of 2-chlorodeoxyadenosine (cladribine, CDA) given by subcutaneous bolus injections to patients with hairy cell…”
Get full text

Effect of Antiretroviral Therapy on Apoptosis Markers and Morphology in Peripheral Lymph Nodes of HIV-Infected Individuals by Ehrhard, S., Wernli, M., Kaufmann, G., Pantaleo, G., Rizzardi, G. P., Gudat, F., Erb, P., Battegay, M.

“…Background: CD4+ T cell depletion and destruction and the involution of the lymphoid tissue are hallmarks of HIV infection. Although the underlying mechanisms…”
Get full text

Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA by JI, J, WERNLI, M, MIELGO, A, BUECHNER, S. A, ERB, P

“…Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor…”
Get full text

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies by LEYVRAZ, S, HERRMANN, R, PESTALOZZI, B, GUILLOU, L, HONEGGER, H. P, CHRISTINAT, A, FEY, M. F, SESSA, C, WERNLI, M, CERNY, T, DIETRICH, D

“…Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term…”
Get full text